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a b s t r a c t
The peptides orexin-A and orexin-B and their G protein-coupled OX1 and OX2 receptors are involved in
multiple physiological processes in the central nervous system and peripheral organs. Altered expression
or signaling dysregulation of orexins and their receptors have been associated with a wide range of
human diseases including narcolepsy, obesity, drug addiction, and cancer. Although orexin-A, its pre-
cursor molecule prepro-orexin and OX1 receptor have been detected in the human normal and hyper-
plastic prostate tissues, their expression and function in the prostate cancer (PCa) remains to be
addressed. Here, we demonstrate for the ﬁrst time the immunohistochemical localization of orexin-A in
human PCa specimens, and the expression of prepro-orexin and OX1 receptor at both protein and mRNA
levels in these tissues. Orexin-A administration to the human androgen-dependent prostate carcinoma
cells LNCaP up-regulates OX1 receptor expression resulting in a decrease of cell survival. Noteworthy,
nanomolar concentrations of the peptide counteract the testosterone-induced nuclear translocation of
the androgen receptor in the cells: the orexin-A action is prevented by the addition of the OX1 receptor
antagonist SB-408124 to the test system. These ﬁndings indicate that orexin-A/OX1 receptor interaction
interferes with the activity of the androgen receptor which regulates PCa onset and progression, thus
suggesting that orexin-A and its receptor might represent novel therapeutic targets to challenge this
aggressive cancer.
© 2015 Elsevier Inc. All rights reserved.
1. Introduction
The neuropeptides orexin-A and orexin-B, both deriving from
the proteolytic cleavage of the precursor molecule prepro-orexin,
bind with different afﬁnity two G protein-coupled receptors,
namely OX1 and OX2 receptors [1,2]. First discovered in rat hypo-
thalamic neurons projecting their axons towards multiple cerebral
areas, orexins and their receptors regulate many functions medi-
ated by the central nervous system such as sleep and wakefulness,
appetite/metabolism, addiction and reward, blood pressure and
heart rate, sexual behavior, and neuroendocrine homeostasis [1e4].
Orexins and their receptors have been also localized in many pe-
ripheral organs where they exert autocrine, paracrine and endo-
crine activities [5,6]. Dysregulation of multiple physiological
processes has been linked to altered expression or functioning of
either central or peripheral orexinergic system [7], and orexin re-
ceptors have been suggested as therapeutic targets for a variety of
human diseases such as insomnia, obesity, drug addiction, cancer
and others [8].
In particular, OX1 receptor has been identiﬁed as a potential
target for colon cancer therapy [9] and, more recently, for prostate
cancer (PCa) therapy [10]. However, while orexin-A and OX1 re-
ceptor activity in HT29-D4, Caco-2, SW480, and LoVo colon cancer
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cell lines [9,11] and in human colon tumor xenografts in a nude
mice model [9] has been well established, the expression and role
of orexin-A and OX1 receptor in both normal and cancer prostate
cell lines and tissues requires further investigations. Indeed, despite
a wide detection of orexin-A and OX1 receptor in the male genital
tract of mammals [12e16], conﬂicting data on their localization in
the human prostate have been reported. Nakabayashi and co-
workers [17] failed to detect orexin-A immunohistochemical
localization and prepro-orexin mRNA expression in the prostate of
healthy subjects, whereas Malendovicz and co-workers [18]
demonstrated the presence of orexin-A and OX2 receptor but not
prepro-orexin and OX1 receptor expression in normal and hyper-
plastic prostate. More recent studies demonstrated the immuno-
histochemical localization of both orexin-A and OX1 receptor and
the expression of prepro-orexin and OX1 receptor at protein and
mRNA levels in normal and hyperplastic prostate tissues [19].
Furthermore, while OX1 receptor expression was demonstrated in
cancerous foci of high grade PCa tissues, no orexin-A localization
was found in the same tissues as well as in normal prostate tissues
[10].
In order to achieve a better understanding of the expression and
the potential role of orexin-A and OX1 receptor in the PCa, here, we
investigated the immunohistochemical localization of orexin-A and
OX1 receptor and the expression of mRNAs coding for prepro-
orexin and OX1 receptor and the relative proteins in PCa surgical
specimens. In vitro studies using the human androgen-dependent
prostate carcinoma cell line LNCaP were also performed to eval-
uate the capability of orexin-A to modulate the activity of the
androgen receptor which is functionally active in advanced and
castration-resistant PCa [20].
2. Materials and methods
2.1. Antibodies and reagents
Rabbit polyclonal anti-orexin-A antibody supplied with its
control peptide (PC362) was obtained fromMillipore (Billerica, MA,
USA); rabbit polyclonal anti-OX1 receptor antibody (PAB8017) from
Abnova (Taipan, Taiwan) and the synthetic blocking peptide
(ab188501) from Abcam (Cambridge, UK); rabbit polyclonal anti-
prepro-orexin antibody (AB3096), its blocking peptide (AG774),
and monoclonal anti-g-tubulin (MAB1637) antibody from Chem-
icon International Inc. (Temecula, CA, USA); biotinylated goat anti-
rabbit (BA-1000) secondary antibody from Vector Laboratories
(Burlingame, CA, USA); horseradish peroxidase goat anti-rabbit IgG
(A-0545) from Sigma Chemical Co. (St. Louis, MO, USA). The peptide
orexin-A (003-30) was purchased from Phoenix Pharmaceuticals
(Karlsruhe, Germany); 3-[4,5-dimethylthiazol-2-yl]-3,5 diphenyl
tetrazolium bromide (MTT) kit from Cayman Chemicals (Ann Arbor,
MI, USA); OX1 receptor inhibitor SB-408124 (1963) from Tocris
Bioscience (Bristol, UK); the primers for human prepro-orexin, OX1
receptor, hypoxanthine ribosyltransferase (HPRT1), and b-actin
from Primm (Milan, Italy).
2.2. Surgical specimens
Human PCa specimens were collected from 15 patients (52e75
year old) hospitalized at the Department of Urology of the “A.
Cardarelli” Hospital (Naples, Italy) who underwent radical prosta-
tectomy. The procedure followed the rules described in the Decla-
ration of Helsinki, and all patients were previously informed about
their contribution. The samples were ﬁxed either in 10% formal-
dehyde in phosphate buffer or in Bouin's ﬂuid for 48 h, dehydrated
in ascending alcohols, clariﬁed in xylene, stored in a methacrylate
solution, and embedded in Paraplast for immunohistochemistry.
Portions of the collected samples were frozen in liquid nitrogen,
and stored at !80 "C for biochemical analyses. Some sections
(5e7 mm) were stained with hematoxylin and eosin (H&E) to
determine the Gleason's score. Five subject samples were lowgrade
(Gleason's score 3 þ 3), ﬁve samples intermediated grade (Glea-
son's score 4þ 3), and ﬁve samples high grade PCa (Gleason's score
4 þ 5).
2.3. Immunohistochemistry
Paraplast prostate sections were deparafﬁnized in xylene, hy-
drated in descending alcohols and incubated in a 3% H2O2 solution
for 30 min to inhibit endogenous peroxidases. Sections were
treated with citrate buffer, pH 6.0, and heated in a microwave oven
two times (5 min each) at 750 w to reveal masked antigens. After
washing in phosphate buffered saline (PBS) and treatment with
normal serum, sections were incubated with anti-orexin-A or anti-
OX1 receptor primary antibody overnight at 4 "C. After washing in
PBS, the sections were incubated with biotinylated secondary an-
tibodies, and thenwith ABC reagent in two separate steps of 30min
each at room temperature. 3-30diaminobenzidine (DAB) was used
as a ﬁnal stain. The preparations were visualized by a Nikon Eclipse
E600 light microscope and micrographs were taken using a Nikon
Coolpix 800 Digital Camera. Control sections were obtained either
substituting the primary antibody with buffer or pre-absorbing the
antibody with an excess (10!6 M) of its blocking peptide. These
controls always resulted to be negative (data not shown). The
speciﬁcity of the anti-orexin-A antibody had been previously tested
in hypothalamus samples from prepro-orexin null mice [21].
2.4. Western blotting
Human PCa tissue samples were homogenized by an Ultraturrax
L-407 at 4 "C with 5 ml/1.5 g tissue of buffer containing 50 mM
TriseHCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 10 mM NaF, 0.5 g/
100 ml deoxycholic acid, 0.1 g/100 ml sodium dodecyl sulphate
(SDS), 1% (v/v) Nonidet P-40, 1 mM phenylmethyl-sulphonyl ﬂuo-
ride, 10 mg/ml aprotinin, 10 mg/ml leupeptin, and 1 mM Na3VO4.
Homogenates were centrifuged at 15,000$ g for 10min at 4 "C. The
total protein amount of supernatants was determined by the Bio-
Rad protein assay. Samples containing equal amount of proteins
(100 mg) were boiled for 5 min in SDS buffer [50 mM TriseHCl (pH
6.8), 2 g/100 ml SDS, 10% (v/v) glycerol, 0.1 g/100 ml bromophenol
blue and 5% (v/v) beta mercaptoethanol], run on a 12.5% SDS/
polyacrylamide gel, and transferred to nitrocellulose using a Mini
trans-blot apparatus (Bio-Rad Laboratories). Membranes were
blocked for 1 h at room temperature with TBS-T buffer [150 mM
NaCl, 20 mM TriseHCl (pH 7.4), 0.1% Tween 20] containing 5 g/
100 ml milk. The blots were incubated overnight with anti-prepro-
orexin or anti-OX1 receptor antibody diluted 1:1000 in TBS-T
containing 2.5 g/100 ml milk. After washing with TBS-T, the blots
were incubated for 1 h with horseradish peroxidase conjugated
anti-rabbit IgG diluted 1:3000 in TBS-T containing 2.5 g/100 ml
milk. The proteins were visualized by enhanced chem-
iluminescence. Tomonitor equal loading of gel lanes, the blots were
stripped and re-probed using an anti-g-tubulin monoclonal
antibody.
2.5. Cell cultures
The LNCaP cells (ATCC® CRL-1740™) were cultured in RPMI 1640
(Euroclone, Pero, MI, Italy) supplemented with 10% heat-
inactivated fetal bovine serum (FBS), 2 mM L-glutamine, 2 mM
sodium pyruvate, 1 $ non essential amino acids, 100 U/ml peni-
cillin,100mg/ml streptomycin, and 10 mg/ml gentamicin. Cells were
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maintained at 37 "C in an humiﬁed incubator with 5% CO2. The
conﬂuent cells were detached by trypsin-EDTA. For quantitative
analysis of OX1 receptor expression levels, freshly re-suspended
cells (3 $ 106) were incubated for 3 h with 10!7 M orexin-A
diluted in serum free culture medium, whereas control cells were
treated with serum free culture medium alone. To evaluate orexin-
A effect on cell survival, we carried out the MTT assay as previously
described [19]. Brieﬂy, 2.5$ 105 LNCaP cells were seeded in 96-well
plates for 24 h. Appropriate concentrations of orexin-A, in the
absence or in the presence of OX1 receptor antagonist SB-408124,
were added to the wells for a 48 h lasting incubation, while con-
trol cells were treated with medium alone. Successively, 10 ml of a
MTT solution were added to each well for 4 h at 37 "C and 5% CO2.
Finally, the culture medium was gently aspirated and replaced by
100 ml of crystal dissolving solution in order to dissolve the for-
mazan crystals. The absorbance of the solubilized dye, which cor-
relates with the number of living cells, was measured by a Synergy
2 (BioTek) microplate reader at 570 nm equipped with a Gen 5
software.
2.6. RNA extraction, reverse transcription (RT) PCR and real time
PCR
Extraction of total RNA from PCa tissues, synthesis of cDNAs for
the detection of human prepro-orexin and OX1 receptor, and RT-
PCR were performed as described previously [15]. For quantita-
tive real time PCR, total RNA from LNCaP cells was extracted using
the PureLink® RNA Mini Kit (Ambion Life Technologies, Monza,
Italy). Contaminating genomic DNA was removed by treatment
with TURBO DNA-free™ Kit (Ambion Life Technologies) and the
total amount of RNAwas quantiﬁed with a Nanodrop spectrometer.
cDNAs were synthesized from 1 to 5 mg RNA using the SuperScript®
II Reverse Transcriptase (Invitrogen Life Technologies) and quanti-
tative PCR was performed by using the 7500 Real-Time PCR System
and SYBR® Select Master Mix 2X assay (Applied Biosystem,
Abbiategrasso, MI, Italy). OX1 receptor and HPRT1 primers were
designed by using Primer Express software version 3.0: OX1 re-
ceptor forward primer 50-CCCCACTGGGCCTCATG-30 and reverse
primer 50-CCCCAGAGCTTGCGGAATA-30; HPTR1 forward primer 50-
CGTCTTGCTCGAGATGTGATG-30 and reverse primer 50-GCACACA-
GAGGGCTACAATGTG-30. The amount of target cDNAwas calculated
by comparative threshold (Ct) method and expressed by means of
the 2!DDCt method [22] using HPRT1 as internal control.
2.7. Androgen receptor nuclear translocation assay
LNCaP cells were seeded in T25 ﬂasks at a density of 1.2 $ 106
cells and incubated for 2 h with increasing concentrations of
orexin-A (from 10!8 to 10-6 M). Some samples, before adding
orexin-A, were treated with 0.4 nM testosterone for 30 min. Some
others were previously treated for 30 min with OX1 receptor
antagonist before adding testosterone. All substances were diluted
in serum free medium which was used also for control cell incu-
bation. Nuclear extract protein concentration was determined us-
ing the colorimetric Pierce method (Thermo Scientiﬁc) loading 8 mg
of nuclear protein extract for each sample in the provided plate.
Androgen receptor nuclear translocation was evaluated by a
sandwich ELISA method (Abcam, Cambridge, UK) reading the
absorbance at 450 nm by a Multiscan Ascent microplate reader
(Thermo Scientiﬁc).
2.8. Statistical analysis
Statistical analysis was performed using a GraphPad Prism
Software (version 5.0). The one-way ANOVA and Bonferroni's
Multiple Comparison tests were used to assess the statistical sig-
niﬁcance of the results obtained from androgen receptor trans-
location assay and real time PCR experiments. P values were
considered signiﬁcant when <0.05 (*), <0.01 (**) and <0.001 (***).
3. Results and discussion
3.1. Immunohistochemical localization of orexin-A and OX1
receptor in PCa tissues
The results obtained by using the avidin-biotin immunohisto-
chemical method showed orexin-A-immunoreactivity (IR) in all
analyzed PCa sections (Fig. 1). Orexin-A-IR appeared as ﬁne gran-
ules present in the cytoplasm of adjacent cells grouped in small
areas, with large zones lacking of positivity. Such granules tended
to cluster in coarse inclusions which sometimes entirely ﬁlled the
cytoplasm, thus becoming easily visible also at low magniﬁcation
(Fig.1a,c). Intensely stained cells appeared to be isolated or grouped
in small clusters (Fig. 1b) or aligned along the circular proﬁle of
structures recognizable as glandular follicles (Fig. 1a,d). Sometimes
the whole epithelium lining a follicle showed a mono- or bi-
stratiﬁed sequence of orexin-A immunoreactive cells. OX1
receptor-IR was also detected in all examined PCa sections (Fig. 2).
Its shape and distribution were closely similar to those described
for orexin-A (Fig. 2aed). Although the data reported are repre-
sentative of orexin-A- and OX1 receptor-IR detected in high grade
PCa tissues, positivity for both orexin-A and OX1 receptor was also
found in PCa samples of low and intermediate grade (data not
shown). These results, while conﬁrmOX1 receptor immunolabeling
in PCa tissues [10], demonstrate for the ﬁrst time orexin-A locali-
zation in the tissues whatever the grade of PCa. The discrepancy
between our ﬁndings and those reported by Alexandre et al. [10],
who failed to detect orexin-A immunostaining in PCa specimens
and OX1 receptor in LNCaP cells, may be ascribed either to the
different methodological procedures (i.e., different primers and
protocols for PCR) or to the high turnover of internalization and/or
cellular production of endocrine substances such as orexins and
their receptors.
3.2. Expression of prepro-orexin and OX1 receptor mRNAs and
proteins in PCa tissues
In order to conﬁrm at molecular level the local presence of
orexin-A and its receptor in the tissues, biochemical analyses were
carried out on frozen PCa specimens. The expression of mRNAs
coding for orexin-A precursor molecule prepro-orexin and OX1
receptor in PCa tissues was analyzed by RT-PCR. This analysis
resulted in the ampliﬁcation of speciﬁc DNA fragments of 393 bp
for prepro-orexin and 356 bp for OX1 receptor in all samples
(Fig. 3A, lns. 3). A 469 bp transcript was obtained from the ampli-
ﬁcation of b-actin cDNA (Fig. 3A, bottom, lns. 2, 3). No ampliﬁcation
products were obtained when distilled water was used in place of
cDNA (negative control) (Fig. 3A, lns. 4), whereas DNA fragments for
prepro-orexin and OX1 receptor were detected in a whole rat brain
homogenate which was used as positive control (Fig. 3A, lns. 2).
The presence of the two proteins prepro-orexin and OX1 re-
ceptor in the PCa tissues was conﬁrmed by Western blotting, using
a rabbit polyclonal antibody raised against a 17 amino acid peptide
mapping near the C-terminus of human prepro-orexin or a rabbit
polyclonal antibody raised against a peptide mapping near the C-
terminus of human OX1 receptor, respectively. The detected pro-
teins showed a molecular mass of 16 kDa as expected for prepro-
orexin (Fig. 3B, upper blot, lns. 2), and 50 kDa as expected for
OX1 receptor (Fig. 3B, middle blot, lns. 2). The speciﬁcity of the
response was conﬁrmed by pre-incubation of the prepro-orexin or
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OX1 receptor antibody with their respective blocking peptides.
There was no expression of prepro-orexin and OX1 receptor in
these preparations (Fig. 3B, lns 3), whereas the presence of the
proteins was detected in the whole rat brain homogenate used as
positive control (Fig. 3B, lns 1). The stripping of the upper blots and
their re-probing with monoclonal anti-g-tubulin antibody
demonstrated equal loading of proteins in all lanes (Fig. 3B,
bottom).
These results deﬁnitely demonstrate the local presence of
orexin-A in the cancerous prostate epithelium. Indeed, we not only
detected orexin-A immunostaining in all analyzed PCa tissues, but
we also found the expression of the orexin-A precursor molecule
prepro-orexin both at mRNA and protein levels, thus suggesting
that OX1 receptor expressed by PCa cells is probably activated by
endogenous orexin-A in vivo.
Fig. 1. Orexin-A-immunoreactivity in high grade PCa tissues. aed: positive cells are scattered in the neoplastic tissue (b) or aligned along the circular proﬁle of glandular follicles
(a,c,d). ced: the granular shape of OxA immunoreactive material in the cytoplasm is clearly visible at higher microscopic magniﬁcation of follicular cells. Avidin-biotin immu-
nohistochemical method. Bars: 20 mm.
Fig. 2. OX1 receptor-immunoreactivity in high grade PCa tissues. Differently shaped positive cells are isolated in the neoplastic tissue (a,b) or organized in small clusters of elements
(c,d) whose cytoplasm shows various staining intensity. The epithelial shape of all positive cells is clear although the original organization of the tissue is lost. Avidin-biotin
immunohistochemical method. Bars: 20 mm.
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3.3. Orexin-A treatment of LNCaP cells up-regulates OX1 receptor
gene expression, and inhibits cell survival
In order to get more insights into the role of orexin-A and its
receptor in the physiopathology of the prostate, we performed
in vitro experiments using the LNCaP cell line. We ﬁrst measured by
real-time PCR the expression levels of mRNA coding for OX1 re-
ceptor in both untreated LNCaP cells and cells exposed to orexin-A
(10!7 M) for 3 h. This quantitative analysis revealed that OX1 re-
ceptor gene is expressed in LNCaP, even though at low extent (mean
Ct value 34,23917), and that orexin-A cell treatment up-regulates
the receptor gene expression (Fig. 3C). Particularly, cell treatment
with a physiological concentration of orexin-A increased by 25%
OX1 receptor gene expression.
The ﬁnding that the expression of OX1 receptor is up-regulated
by LNCaP cell exposure to orexin-A is consistent with previous data
showing that orexin-A treatment stimulates the expression of OX1
receptor gene in luteal and follicular cells of the rat ovary [23],
cultured rat calvarial osteoblast-like (ROB) cells [24], rat insulin-
secreting beta-cell line (INS-1 cells) [25] and in rat hepatocytes
[26]. In these latter cell types, orexin-A mediated OX1 receptor up-
regulation results in cell proliferation increase and protection of
cells from apoptosis [25,26], whereas it exerts a notable inhibitory
effect on the proliferative activity of ROB cells [24]. Thus, we eval-
uated by MTT assay whether orexin-A induced up-regulation of
OX1 receptor in LNCaP cells would affect cell survival. The results
showed that 10!7 M orexin-A causes a statistically signiﬁcant
decrease of LNCaP cell survival with respect to control cells
(Fig. 4A). The addition to the test system of OX1 receptor antagonist
SB-408124 prevented the orexin-A inhibitory effect on cell survival.
Further investigations are in progress to establish whether the
orexin-A/OX1 receptor interaction mediates apoptosis in LNCaP
cells.
3.4. Orexin-A counteracts testosterone-induced nuclear
translocation of androgen receptor in LNCaP cells
The prostate is an androgen-dependent organ which synthe-
sises the androgen receptor, a hormone activated transcription
Fig. 3. Expression of prepro-orexin and OX1 receptor in PCa tissues and OX1 receptor
up-regulation by orexin-A in LNCaP cells. A. RT-PCR. Lane 1, DNA ladder; lane 2,
prepro-orexin (upper) or OX1 receptor mRNA transcripts in whole rat brain sample
(positive control); lane 3, prepro-orexin or OX1 receptor mRNA transcripts in PCa
tissue samples; lane 4, negative control (no cDNA input). The bottom reports the b-
actin mRNA transcripts in all samples (internal control). B. Western blotting. Lane 1,
homogenate from whole rat brain (positive control); lane 2, homogenate from PCa
tissues; lane 3, prostate homogenate treated with the antisera directed against prepro-
orexin (upper blot) or OX1 receptor pre-absorbed with their respective control pep-
tides (negative control). The blots were stripped and re-probed with an anti-g-tubulin
monoclonal antibody to ensure equal loading of proteins in all lanes (lower blot).
Molecular mass markers are indicated on the left. C. Expression of OX1 receptor mRNA
in control (Ctrl) or orexin-A (10!7 M) treated LNCaP cells as measured by real time PCR.
OX1 receptor mRNA levels are expressed in arbitrary units (a.u.). **P < 0.01. Similar
results of those reported in A, B, and C were obtained from ﬁve separate experiments
of identical design.
Fig. 4. A. Effect of orexin-A on the LNCaP cell survival. Orexin-A was added to LNCaP
cells and after 48 h MTT assay was performed. Orexin-A at the doses of 10!7 M caused
a decrease of cell survival (P < 0.05) as compared to control (ctrl) cells. The adminis-
tration of OX1 receptor antagonist SB-408124 (OX1ri) reversed the effect of orexin-A.
B. Effect of orexin-A on the nuclear translocation of androgen receptor in LNCaP cells in
absence and presence of testosterone. Different concentrations of orexin-A did not
induce nuclear translocation of the androgen receptor in native LNCaP cells.
Conversely, orexin-A at the doses of 10!7 and 10!8 M induced a signiﬁcant reduction of
the nuclear translocation of the androgen receptor after testosterone (0.4 nM) cell pre-
treatment. Cell pre-treatment with OX1 receptor antagonist SB-408124 resulted in the
inhibition of the testosterone-dependent effect of orexin-A on androgen receptor
nuclear translocation. The administration of SB-408124 alone to the cells had no effect.
The bar diagrams represents the means ± SE. *P < 0.05, ***P < 0.001 (versus the
testosterone sample). The data reported in A and B are the means of three independent
experiments performed with each sample in replicate of three.
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factor. The metabolic functions of androgen receptor in normal
prostate are circumvented in PCa to drive tumor growth, and the
androgen receptor acquires growth-promoting functions during
PCa development and progression through both genetic and
epigenetic mechanisms [27]. Thus, the biological pathways pro-
moting proliferation, differentiation and survival of malignant
prostate tissues are strictly regulated by androgens and androgen
receptor activity. Beside surgery, androgen deprivation therapy
represents the primary treatment for PCa at the moment. However,
PCas may become resistant to the therapy within two years, and
relapse invariably occurs in castration-resistant PCa (CRPC).
Several mechanisms for castration resistance have been pro-
posed, including the reactivation of androgen receptor signaling in
patients who have previously undergone castration therapy
[20,27]. Indeed, the androgen receptor is highly expressed and
functionally active in CRPC due to androgen synthesis from adrenal
steroids. Despite very low circulating levels of ligand, androgen
receptor signaling is maintained by multiple mechanisms, and a
wide array of factors has been implicated in androgen receptor
stimulation in the development of CRPC. These factors include an
increased expression of the androgen receptor, mutations that
confer broader ligand speciﬁcity to the receptor, changes in the
ratios between the androgen receptor and its co-regulators, and up-
regulation of cross-talk signal transduction pathways that can
activate the androgen receptor in a ligand-independent manner
[27]. Thus, the androgen receptor signaling has been pinpointed as
a target for the development of novel therapies for CRPC treatment
[20].
In this study, we evaluated whether orexin-A shows the capa-
bility to affect androgen receptor activity in LNCaP cells. In partic-
ular, the effect of orexin-A on androgen receptor nuclear
translocation in LNCaP cells was evaluated both in the absence or in
the presence of exogenous testosterone. The results obtained
showed that cell exposure to orexin-A alone, in a concentration
range from 10!8 M to 10!6 M, does not affect androgen receptor
translocation in LNCaP cells (Fig. 4B). Conversely, in the presence of
nanomolar concentrations of testosterone, low doses of orexin-A
(10!7 and 10!8 M) caused a signiﬁcant reduction of androgen re-
ceptor nuclear translocation in LNCaP. The effect of orexin-A was
fully inhibited by adding to the test system the OX1 receptor
antagonist SB-408124. These data demonstrate that orexin-A/OX1
receptor interaction is able to antagonize testosterone-induced
androgen receptor nuclear translocation, thus suggesting that
orexin-A might play a role in the regulation of androgen/androgen
receptor signaling in PCa. The potential role of orexin-A as a co-
regulator of the androgen receptor activity in PCa is an intriguing
topic that deserves further in depth investigations for the devel-
opment of novel therapies for the cure of this cancer.
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